CN112006282A - 一种修复糖尿病并发症的组合物及其制备方法与应用 - Google Patents
一种修复糖尿病并发症的组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN112006282A CN112006282A CN202010923507.XA CN202010923507A CN112006282A CN 112006282 A CN112006282 A CN 112006282A CN 202010923507 A CN202010923507 A CN 202010923507A CN 112006282 A CN112006282 A CN 112006282A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- diabetic
- weight
- repairing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 54
- 206010012655 Diabetic complications Diseases 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 47
- 239000008280 blood Substances 0.000 claims abstract description 47
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 40
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 40
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 39
- 208000008960 Diabetic foot Diseases 0.000 claims abstract description 32
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 208000010837 Diabetic eye disease Diseases 0.000 claims abstract description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 8
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- 239000001301 oxygen Substances 0.000 claims abstract description 8
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 56
- 235000013325 dietary fiber Nutrition 0.000 claims description 36
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 34
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 34
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 34
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 34
- 235000010930 zeaxanthin Nutrition 0.000 claims description 34
- 239000001775 zeaxanthin Substances 0.000 claims description 34
- 229940043269 zeaxanthin Drugs 0.000 claims description 34
- 240000000249 Morus alba Species 0.000 claims description 33
- 235000008708 Morus alba Nutrition 0.000 claims description 33
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 30
- 229940054810 white kidney bean extract Drugs 0.000 claims description 30
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 27
- 235000012680 lutein Nutrition 0.000 claims description 22
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 22
- 229960005375 lutein Drugs 0.000 claims description 22
- 239000001656 lutein Substances 0.000 claims description 22
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 22
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 7
- 239000007910 chewable tablet Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 235000015110 jellies Nutrition 0.000 claims description 5
- 239000008274 jelly Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 4
- 229940068682 chewable tablet Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 238000007796 conventional method Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 230000001603 reducing effect Effects 0.000 abstract description 19
- 239000002994 raw material Substances 0.000 abstract description 5
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 206010052428 Wound Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 229920002674 hyaluronan Polymers 0.000 description 15
- 229960003160 hyaluronic acid Drugs 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 14
- YHGJHDJZIOYZIR-URPSFYETSA-N Helenien Chemical compound CC1(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@@H]1C(C)(C)C[C@@H](OC(=O)CCCCCCCCCCCCCCC)C=C1C YHGJHDJZIOYZIR-URPSFYETSA-N 0.000 description 14
- YHGJHDJZIOYZIR-KFTCWRDFSA-N Helenien Natural products O=C(O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)/C)\C)/C)C(C)(C)C1)CCCCCCCCCCCCCCC YHGJHDJZIOYZIR-KFTCWRDFSA-N 0.000 description 14
- YHGJHDJZIOYZIR-UHFFFAOYSA-N all-trans-lutein dipalmitate Natural products CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)(C)CC(OC(=O)CCCCCCCCCCCCCCC)C=C1C YHGJHDJZIOYZIR-UHFFFAOYSA-N 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 210000001508 eye Anatomy 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 11
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 235000021158 dinner Nutrition 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 229940118019 malondialdehyde Drugs 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- 230000004310 photopic vision Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 238000005303 weighing Methods 0.000 description 11
- 235000003805 Musa ABB Group Nutrition 0.000 description 10
- 240000008790 Musa x paradisiaca Species 0.000 description 10
- 244000046052 Phaseolus vulgaris Species 0.000 description 10
- 235000015266 Plantago major Nutrition 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229920002907 Guar gum Polymers 0.000 description 9
- 230000004438 eyesight Effects 0.000 description 9
- 239000000665 guar gum Substances 0.000 description 9
- 235000010417 guar gum Nutrition 0.000 description 9
- 229960002154 guar gum Drugs 0.000 description 9
- 239000010903 husk Substances 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 229920000161 Locust bean gum Polymers 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000711 locust bean gum Substances 0.000 description 8
- 235000010420 locust bean gum Nutrition 0.000 description 8
- 229910052753 mercury Inorganic materials 0.000 description 8
- 230000002688 persistence Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 235000011888 snacks Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000000291 postprandial effect Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000001814 pectin Substances 0.000 description 6
- 229920001277 pectin Polymers 0.000 description 6
- 235000010987 pectin Nutrition 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- -1 small molecule compound Chemical class 0.000 description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 235000008429 bread Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000010453 quartz Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010053615 Thermal burn Diseases 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000643 oven drying Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- 108050007957 Cadherin Proteins 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 150000002016 disaccharides Chemical group 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000021332 kidney beans Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Chemical group CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Chemical group CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 208000031662 Noncommunicable disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 241000220435 Papilionoideae Species 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012667 Diabetic glaucoma Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010049927 Dry gangrene Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000219833 Phaseolus Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 238000012193 PureLink RNA Mini Kit Methods 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101100496572 Rattus norvegicus C6 gene Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 102000036211 hyaluronic acid binding proteins Human genes 0.000 description 1
- 108091010998 hyaluronic acid binding proteins Proteins 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229940107604 lutein esters Drugs 0.000 description 1
- 150000002658 luteins Chemical class 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000008437 mitochondrial biogenesis Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000017376 neurovascular disease Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于功能食品加工技术领域，特别涉及一种修复糖尿病并发症的组合物，并进一步公开其制备方法，以及其制备多功能食品的用途。本发明所述修复糖尿病并发症的多功能组合物，以含氧类胡萝卜素、壳寡糖、透明质酸钠等为原料制得，基于上述各原料组分的有机协同作用，具有修复和预防糖尿病足及糖尿病眼病的作用，可用于修复糖尿病足、修复糖尿病眼病、降低血糖、降低血脂以及减肥、美容等领域的应用。
Description
技术领域
本发明属于功能食品加工技术领域，特别涉及一种修复糖尿病并发症的组合物，并进一步公开其制备方法，以及其制备多功能食品的用途。
背景技术
近些年，随着中国经济的发展和社会的进步，人们的饮食和生活方式也产生了很大的变化，由此也引发了疾病谱的显著改变。其中，慢性非传染性疾病己经成为威胁人群健康的主要疾病，据2016年死因监测的数据显示，中国居民因慢性非传染性疾病(简称“慢性病”)造成的死亡占全部死亡的87.8％。
糖尿病作为常见且主要的慢性病之一，是由遗传因素、生活方式和环境因素相互作用引起的一组以高血糖为特征的内分泌代谢性疾病。糖尿病分为1型糖尿病、2型糖尿病、妊娠期糖尿病以及特殊类型糖尿病(例如胰腺外分泌疾病、内分泌性疾病及感染等)。糖尿病患者由于高血糖的长期存在，可能会影响全身的各个器官和组织，尤其是可引起眼、肾脏、心脏、血管、神经等的慢性损害。尤其是近年来，世界各国的糖尿病患病率均呈现出上升趋势，尤其以发展中国家增长更加迅速。中国作为目前世界上糖尿病患者数最多的国家，患者数占世界总数的近四分之一，其血糖控制及并发症的诊治消耗了大量的医疗资源。
糖尿病患者的并发症如糖尿病足、糖尿病眼病、糖尿病肾病、糖尿病心血管并发症、糖尿病性脑血管病、糖尿病神经病变等严重影响了人们的生活质量。其中，糖尿病足和糖尿病眼病是糖尿病常见且主要的并发症。糖尿病足的发病机制主要是由于机体长期处于高血糖状态，导致局部神经血管病变，引起组织慢性缺血缺氧，严重者组织坏死，溃疡。研究表明国内糖尿病足发生率可高达14.5％。其临床主要表现为：麻木、疼痛，重者形成湿性或干性坏疽，随后甚至截肢，严重影响患者的生活质量，给患者身心也造成巨大创伤，带来身心疾病。糖尿病眼病是常见的一种慢性糖尿病并发症，临床表现为眼压增高、难以解释的眼部不适症状、视网膜病变、戴眼镜后视力减退、黄斑水肿、其他可以危及视力的眼科病变等，甚至可引起患者眼部多种疾病甚至失明。有资料表明，病程20年以上的糖尿病患者，几乎均有眼部并发症的发生，这些眼部并发症的损害程度可能与年龄增长和血糖代谢异常的程度密切相关。糖尿病眼病临床最常见的主要有糖尿病视网膜病变、糖尿病性白内障以及糖尿病性青光眼，这三种常见糖尿病眼部并发症均是导致糖尿病患者失明的主要原因。
目前，临床对于糖尿病及其并发症并没有理想的治愈方法，仍然主要以控制血糖为主。针对于糖尿病足的治疗主要是用外用药物或器械，改善创面血管生成、增加组织血流灌注、神经再生等方面，防止足部感染或进一步恶化；糖尿病眼病的治疗也主要是用眼部外用药物、中药、针灸等方式针对症状进行治疗。但这些方法往往成本高，副作用大，而且疗效不明显。
发明内容
为此，本发明所要解决的技术问题在于提供一种具有降低血糖，修复糖尿病足和糖尿病眼病、降低血脂、减肥、美容等功能的组合物，具有营养丰富、制备方法简单、食用方便，口感佳，无毒无副作用的优势；
本发明所要解决的第二个技术问题在于提供上述组合物的制备方法以及其制备的多功能食品。
为解决上述技术问题，本发明所述的一种修复糖尿病并发症的组合物，包括0.2-4重量份的含氧类胡萝卜素、2-20重量份的壳寡糖、以及2-20重量份的透明质酸钠。
进一步，所述含氧类胡萝卜素包括0.1-2重量份的玉米黄质以及0.1-2重量份的叶黄素和/或其酯类。
进一步，所述组合物还包括2-15重量份的桑叶提取物和2-15重量份的白芸豆提取物。
进一步，所述组合物还包括3-60重量份的膳食纤维。
进一步，所述组合物还包括1-50重量份的L-阿拉伯糖。
具体的，所述修复糖尿病并发症的组合物，包括：
玉米黄质0.1-2重量份；
叶黄素和/或其酯类0.1-2重量份；
壳寡糖2-20重量份；
透明质酸钠2-20重量份；
桑叶提取物2-15重量份；
白芸豆提取物2-15重量份；
膳食纤维3-60重量份；
L-阿拉伯糖1-50重量份。
具体的，所述修复糖尿病并发症的组合物，包括：
玉米黄质0.1-1重量份；
叶黄素和/或其酯类0.1-1重量份；
壳寡糖3-20重量份；
透明质酸钠3-20重量份；
桑叶提取物3-10重量份；
白芸豆提取物3-10重量份；
膳食纤维6-60重量份；
L-阿拉伯糖3-50重量份。
具体的，所述膳食纤维包括β-葡聚糖可溶性纤维、车前子壳粉、纤维素、瓜尔豆胶、果胶、槐树豆胶、羟丙甲纤维素中的至少一种。
具体的，所述透明质酸钠为小分子化合物，其分子量在1200-300000道尔顿之间，并优选所述透明质酸钠的分子量在1600-5000道尔顿之间。
具体的，所述桑叶提取物为桑叶的醇提取物。
具体的，所述白芸豆提取物为白芸豆的水提取物。
本发明还公开了由所述组合物添加可接受的常规辅料、并按照常规工艺制备的修复糖尿病并发症的食品、保健品或药物制剂。
具体的，所述的食品、保健品或药物制剂，包括粉剂、颗粒剂、散剂、软糖、果冻、口服液、胶囊、冲剂、片剂或咀嚼片。
本发明还公开了一种制备所述食品、保健品或药物制剂的方法，包括取选定量的组合物各组分充分混匀的步骤，以及加入选定辅料混合，并按照常规工艺制成选定剂型的步骤。
本发明还公开了所述组合物用于制备修复糖尿病并发症的食品、保健品或药物制剂的用途，具体的，所述糖尿病并发症包括降低血糖、降低血脂、糖尿病足、糖尿病眼病。
本发明还公开了所述组合物用于制备具有减肥、美容效果的食品、保健品或药物制剂的用途。
本发明所述修复糖尿病并发症的多功能组合物，以含氧类胡萝卜素、壳寡糖、透明质酸钠等为原料制得，可配合辅料制备成各种剂型的多功能食品，如粉剂、咀嚼片、口服液、软糖等等；其中，
叶黄素酯可在体内分解出叶黄素。叶黄素和玉米黄质是天然色素，属于含氧类胡萝卜素，二者在结构上互为同分异构体，人体不能直接合成叶黄素和玉米黄质。叶黄素和玉米黄质广泛分布在人体血清、肝脏等组织中，其中视网膜黄斑中密度最高，它们是阻止光暴露引起视网膜损伤的最有效成分。叶黄素主要沉积在视网膜中间凹部位，而玉米黄质在视网膜中分布则较分散，此两种物质进入视网膜是由特定叶黄素结合蛋白介导的。越来越多流行病学和临床试验表明，膳食或血清中较高含量的叶黄素和玉米黄质可降低眼部疾病患病风险，叶黄素和玉米黄质可阻止年龄相关性黄斑变性(AMD)的形成和发展，补充叶黄素和玉米黄质可改善AMD患者视力；
壳寡糖(chitooligosaccharides,COS)是壳聚糖(CTS)经酶促反应或化学降解而得的低聚物，聚合度为2-20，是目前自然界唯一带正电荷的碱性氨基寡糖。壳寡糖无毒、相对分子质量低、水溶性较好、生物活性高、易被人体吸收利用，具有调节免疫、抗炎、抗菌、抗氧化、降血脂、降血糖和抗肿瘤等多种生物活性。此外，有研究表明，壳寡糖对肾脏具有较好的保护和缓解作用，而且COS剂量越高产生的作用效果越明显；能抑制炎症因子释放，因而其对炎性肠病有较好的防治作用；壳寡糖还可以通过促进脾脏和胸腺的生长、诱导多种免疫细胞产生细胞因子等途径来增强机体的免疫应答；可显著促进胰岛细胞的增殖和胰岛素的释放；可降低其血糖水平，缓解自由基代谢紊乱；可作为线粒体生物发生的新型诱导剂来增强运动耐力；
透明质酸(hyaluronic acid,HA)是一种非硫酸化的高分子线性多糖，基本结构是由D-葡萄糖醛酸和N-乙酰氨基葡糖的双糖单位组成。D-葡萄糖醛酸及N-乙酰葡糖胺之间由β-1,3-配糖键相连，双糖单位之间由β-1,4-配糖键相连。大部分组织中含有的天然透明质酸分子量介于1000-10000kDa。HA在细胞运动、细胞黏附和增殖过程中发挥作用主要是通过两种HA受体介导实施的，分别是CD44和RHAMM(the receptor for HA-mediated motility，也叫CD168)。HA具有良好的减肥效果，不仅可以降低体质量，还可以减少脂肪组织和血清低密度脂蛋白-胆固醇，以及总胆固醇和瘦素水平，同时可以降低脂肪组织的过度肥大，改善脂肪肝。研究者发现，通过体内组织学变化和皱纹指标，HA可以治愈由紫外线B波照射引起的皮肤伤害。HA和透明质酸结合蛋白通过调控炎症细胞浸润、炎症细胞因子的释放和细胞的迁移来调控炎症及组织损伤的修复。因此，HA可以作为人类疾病中的一种免疫调节剂。低分子量HA具有保护肉芽组织生长，防止其受到自由基的损伤作用，进而有效促进伤口的愈合。寡聚HA在体外能够对大鼠C6神经瘤细胞、人LX1肺癌细胞、人HCT克隆细胞的增长具有较强的抑制作用，抑制率能够达到50％-100％。寡聚HA的应用能够促进血管内部细胞的转移与生长，进而实现促进血管生成的作用。同时，寡聚HA的应用还能够在内皮细胞当中使VⅢ型胶原与I型胶原相结合，二者在血管生成过程中具有十分关键的作用。本发明所用的透明质酸钠的分子量为1200-300000道尔顿，进一步优化为1200-5000道尔顿，充分发挥小分子透明质酸钠的体内循环功能，具有减肥、免疫调节等作用。
白芸豆(white kidney bean)属豆科(Leguminosae)，蝶形花亚科(Papilionoideae)，菜豆族菜豆属，原产美洲的阿根廷和墨西哥，后经人工栽培驯化已适应冷凉潮湿的高原地带。白芸豆营养丰富，具有较高的食用价值和药用价值，白芸豆所含的蛋白质属于全价蛋白，接近动物蛋白，富含人体必需的氨基酸，每100g干豆所含蛋白质高达20.0％，含脂肪1.6％-2.1％、碳水化合物37.6％-48.5％、胡萝卜素0.24mg、钙160mg、铁10mg，还有丰富的B族维生素以及维生素C。白芸豆富含α-淀粉酶抑制剂和膳食纤维，α-淀粉酶属于糖苷水解酶抑制剂的一种，国外称之为“淀粉阻断剂”。它能有效阻断高淀粉类食物(杂粮、面食、米饭及相关糕点和零食)中淀粉的分解，阻断部分淀粉热量的摄取，减少人体的脂肪来源，达到降低热量摄入的目的。目前国内开发出一种白芸豆精华素的产品，能抑制α-淀粉酶的作用，阻断淀粉分解，减少葡萄糖吸收，从而起到降低餐后血糖升高，减少胰岛素分泌，降低脂肪合成等作用，可以有效配合糖尿病人和减肥者的饮食治疗，使他们饭吃饱、消除饥饿感，而餐后血糖不高，体重不增；
桑叶又名铁扇子，《本草纲目》称其为“神仙草”，为桑科植物桑(Morus alba L.)的干燥叶，桑叶性苦、寒、甘，归肝、肺经，具有疏散风热、清肝明目、清肺润燥的功效，在临床上主要用于治疗风热感冒，肺热燥咳，头晕头痛，目赤昏花等。研究发现桑叶含有生物碱、多糖、甾醇类、黄酮、氨基酸、矿物质和维生素等多种功能成分。现代药理学研究表明桑叶提取物具有降血糖、抗炎、抗菌、抗病毒、清除自由基、抗衰老、抗癌、降血脂、降血压、保护心脑血管、改善消化功能等生物活性；
所述膳食纤维是目前公认的可作为食品原料应用的膳食纤维，即β-葡聚糖可溶性纤维、车前子壳粉、纤维素、瓜尔豆胶、果胶、槐树豆胶、羟丙甲纤维素中的一种或多种组合；膳食纤维(dietary fiber，DF)最早由Hipsley提出，是一类不能被人体消化酶消化、也不能被小肠吸收的以多糖为主的高分子物质的总称，主要成分包括纤维素、半纤维素、木质素及树胶、果胶、黏质等。膳食纤维被称为人类的第七大营养素，享有“肠道清洁夫”和“生命绿洲”的美称，膳食纤维作为不能被人体内源性消化酶消化吸收的糖类，具有饱腹、延缓消化、降低小肠吸收等作用，且能量较少，具有减少血糖、血脂的吸收和改善血糖的作用，对肥胖的发生和预防起重要作用。现代研究表明膳食纤维对预防龋齿、防止便秘、减肥、降低血压等都有一定的作用，除此之外，膳食纤维还对降低与荷尔蒙相关的癌症(如乳腺癌等)有一定的功效；
L-阿拉伯糖是一种自然界中天然存在的五碳醛糖，是一种没有热量的甜料。L-阿拉伯糖本身带有甜味，甜度相当于蔗糖的一半，是一种可用于替代蔗糖的甜味剂。近年研究发现L-阿拉伯糖在小肠中抑制水解双糖的酶，从而抑制因摄入蔗糖而导致的血糖升高，因此，可以抑制肥胖、预防并治疗与高血糖相关的疾病。因此可以作为一种新型甜味剂为糖尿病人、肥胖者、高血压患者所食用。自然状态的阿拉伯糖以L-形式存在，它不能被动物代谢，因此是一种非热量糖；
本发明所述组合物基于上述各原料组分的有机协同作用，能显著的降低血糖、降低血脂(降低血液中T-CHO、TG值)，并能够减轻紫外线和蓝光等有害光对眼睛的损伤，并可修复眼睛光损伤，延缓眼睛老化及防止病变；同时，本发明所述组合物具有血管扩张功能，改善眼底血液微循环，促进营养物质供应，可促进视网膜细胞中视紫素的生成，预防高度近视及视网膜剥离，增进视力，保护视力，由糖尿病所引起的视网膜病变患者的人士服用，能够使症状减轻，效果显著。经药理研究表明，本发明所述组合物可显著降低糖尿病大鼠的炎症因子CRP，IL-6和NO水平，能显著抑制糖尿病足溃疡创面组织中NF和JNK通路的表达，从而降低创面炎症反应强度，促进创面愈合，具有修复和预防糖尿病足及糖尿病眼病的作用，可用于修复糖尿病足、修复糖尿病眼病、降低血糖、降低血脂以及减肥、美容等领域的应用。本发明所述组合物可制成易于日常服用的食品、保健品或药物制剂等，不仅营养丰富、制备方法简单、食用方便、口感佳，且无毒无副作用，可长期服用。
附图说明
为了使本发明的内容更容易被清楚的理解，下面根据本发明的具体实施例并结合附图，对本发明作进一步详细的说明，其中，
图1为各处理组炎症因子ELISA的测定结果；
图2为各组血管生成因子的免疫组化结果；
图3为各组炎症相关通路指标WB检结果。
具体实施方式
本发明下述实施例中：
所述透明质酸钠为小分子化合物，优选所述透明质酸钠的分子量在1600-5000道尔顿之间；
所述桑叶提取物按照如下步骤提取：取干燥桑叶，粉碎并过20目筛，置提取器中，按照质量体积比(1：20)加入50％的乙醇溶液，浸泡30min，回流提取3次，每次1h，合并滤液减压浓缩后，真空干燥，即得桑叶提取物；
所述白芸豆提取物按照如下步骤提取：取白芸豆至提取器中，按照质量体积比(1：20)加入水，浸泡30min，高压锅内蒸30min，取出过滤，再加水回流提取2次，每次1h，合并全部滤液，减压浓缩后，真空干燥，即得白芸豆提取物。
实施例1
本实施例所述修复糖尿病并发症的组合物，包括：
玉米黄质0.5重量份、叶黄素0.5重量份、壳寡糖10重量份、小分子透明质酸钠(平均分子量为1600道尔顿)10重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维49重量份(其中，车前子壳粉20重量份、槐树豆胶20重量份、β-葡聚糖可溶性纤维9重量份)、L-阿拉伯糖10重量份。
本实施例所述修复糖尿病并发症的组合物制备成食用粉末，具体包括如下步骤：
(a)称取选定质量含量的玉米黄质、叶黄素、壳寡糖、透明质酸钠(小分子)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖适量，混合均匀；
(b)将混合粉末直接分装成3g/袋；
(c)经紫外辐射灭菌即得食用粉末。
本实施例所述食用粉末可直接食用，可作为零食或者佐餐食用，可与牛奶同食，可与正餐同食，建议用量为每日3次，每次1袋。
实施例2
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质0.2重量份、叶黄素0.2重量份、壳寡糖5重量份、小分子透明质酸钠(平均分子量为3000道尔顿)10重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维44重量份(包括车前子壳粉20重量份、瓜尔豆胶24重量份)、L-阿拉伯糖20.6重量份。
本实施例所述修复糖尿病并发症的组合物制备成食用片剂，具体包括如下步骤：
(a)按处方量称取玉米黄质、叶黄素、壳寡糖、透明质酸钠(小分子)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖，混合均匀，过60目筛；
(b)向上述混合物中加入7％的75％的乙醇，制粒；于50℃烘箱干燥(约2h)，过20目筛整粒；
(c)继续加入辅料硬脂酸镁(0.6重量份)，再混合均匀，压片机直接压片，3g/片；
(d)经紫外辐射灭菌即得片剂。
本实施例所述食用片剂可直接食用，可作为零食或者佐餐食用，可与牛奶同食，可与正餐同食，建议用量为每日3次，每次1片。
实施例3
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质0.4重量份、叶黄素二棕榈酸酯0.4重量份、壳寡糖5.2重量份、小分子透明质酸钠(平均分子量为5000道尔顿)10重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维54重量份(其中，果胶25重量份、槐树豆胶29重量份)、L-阿拉伯糖10重量份。
本实施例所述修复糖尿病并发症的组合物制备成胶囊，具体包括如下步骤：
(a)称取选定含量比例的玉米黄质、叶黄素二棕榈酸酯、壳寡糖、透明质酸钠(小分子)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖适量，混合均匀；
(b)粉末直接装胶囊，1g/粒；
(c)经紫外辐射灭菌。
本实施例制备胶囊可作为佐餐食用，可与牛奶同食，也可与正餐同食，建议用量为每日3次，每次3粒。
实施例4
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质0.5重量份、叶黄素二棕榈酸酯0.5重量份、壳寡糖6重量份、小分子透明质酸钠(平均分子量为3000道尔顿)6重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维46重量份(其中，果胶30重量份、槐树豆胶16重量份)、L-阿拉伯糖21重量份。
本实施例所述修复糖尿病并发症的组合物制备成果冻，具体步骤包括：
(a)称取玉米黄质、叶黄素二棕榈酸酯、壳寡糖、透明质酸钠(小分子)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖适量，混合均匀；
(b)粉末加入9倍量的水，煮沸后，加总量1％的琼脂粉，分装成每瓶30mL后，高压灭菌，灭菌后取出放凉，即得果冻。
本实施例所述修复糖尿病并发症的果冻可作为佐餐食用，可与牛奶同食，可与正餐同食，建议用量为每日3次，每次1杯。
实施例5
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质0.5重量份、叶黄素二棕榈酸酯0.5重量份、壳寡糖5重量份、小分子透明质酸钠(平均分子量为3000道尔顿)8重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维26重量份(其中，车前子壳粉16重量份、瓜尔豆胶10重量份)、L-阿拉伯糖40重量份。
本实施例所述修复糖尿病并发症的组合物制备成咀嚼片，具体步骤包括：
(a)按照处方量称取玉米黄质、叶黄素二棕榈酸酯、壳寡糖、透明质酸钠(小分子)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖，混合均匀，并加入苹果酸(2重量份)，混匀过60目筛；
(b)加7％的75％的乙醇制粒，然后在50℃条件下烘干(2h左右)；
(c)过20目筛整粒，加入微粉硅胶(2重量份)、硬脂酸镁(2重量份)为润滑剂混匀后压片，3g/片；
(d)紫外辐射灭菌即得咀嚼片。
本实施例所述修复糖尿病并发症的咀嚼片，可将咀嚼片直接食用，可作为零食或者佐餐食用，可与牛奶同食，可与正餐同食，建议用量为每日3次，每次1片。
实施例6
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质0.5重量份、叶黄素二棕榈酸酯0.5重量份、壳寡糖5重量份、小分子透明质酸钠(平均分子量为1600道尔顿)8重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维26重量份(其中，车前子壳粉16重量份、瓜尔豆胶10重量份)、L-阿拉伯糖40重量份。
本实施例所述修复糖尿病并发症的组合物制备成软糖，具体步骤包括：
(a)按照处方量称取玉米黄质、叶黄素二棕榈酸酯、壳寡糖、透明质酸钠(平均分子量为1600道尔顿)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖、苹果酸(2重量份)混合均匀，加5倍水加热溶解，待全部溶解后加入复合凝胶剂(4％，含明胶2％、琼脂0.5、结冷胶1.5％)，熬煮；
(b)熬糖温度控制在115℃左右，用筷子沾取糖浆观察溶液浓度，当糖液从筷子流下呈细短糖条且不易断落状，停止熬煮；
(c)待糖膏温度下降至70℃时，将糖膏放入数显鼓风干燥箱中灭菌消毒；
(d)冷却成型：将灭菌后的糖膏放入已擦过少量植物油的清洁冷盘内静置冷却并分切成型，放入恒温水浴锅中干燥浓缩成品，1.5g/粒。
本实施例所述修复糖尿病并发症的软糖，可将软糖直接食用，可作为零食或者佐餐食用，可与牛奶同食，可与正餐同食，建议用量为每日3次，每次2粒。
实施例7
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质0.5重量份、叶黄素二棕榈酸酯0.5重量份、壳寡糖6重量份、小分子透明质酸钠(平均分子量为5000道尔顿)6重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维47重量份(其中，果胶30重量份/槐树豆胶17重量份)、L-阿拉伯糖20重量份。
本实施例所述修复糖尿病并发症的组合物制备成口服液，具体包括如下步骤：
(a)称取玉米黄质、叶黄素二棕榈酸酯、壳寡糖、透明质酸钠(小分子)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖适量，混合均匀；
(b)粉末加10倍量的水，煮沸，浓缩至密度为1.30g/mL，分装成每瓶10mL后，高压灭菌，灭菌后取出放凉，即得口服液。
本实施例所述修复糖尿病并发症的口服液，可作为佐餐食用，可与牛奶同食，可与正餐同食。建议用量为每日3次，每次1瓶。
实施例8
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质0.5重量份、叶黄素二棕榈酸酯0.5重量份、壳寡糖5重量份、小分子透明质酸钠(平均分子量为3000道尔顿)10重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维34重量份(其中，车前子壳粉10重量份、瓜尔豆胶24重量份)、L-阿拉伯糖30重量份。
本实施例所述修复糖尿病并发症的组合物制备成颗粒剂，具体包括如下步骤：
(a)按处方量称取玉米黄质、叶黄素二棕榈酸酯、壳寡糖、透明质酸钠(小分子)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖，混合均匀，过60目筛；
(b)加入7％的75％的乙醇，制粒；50℃烘箱干燥(约2h)，过20目筛整粒；
(c)分装，3g/袋；
(d)紫外辐射灭菌即得颗粒剂。
本实施例所述修复糖尿病并发症的颗粒剂，可将片剂直接食用，可作为零食或者佐餐食用，可与牛奶同食，可与正餐同食，建议用量为每日3次，每次1袋。
实施例9
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质0.3重量份、叶黄素0.3重量份、壳寡糖10重量份、小分子透明质酸钠(平均分子量为3000道尔顿)10重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维29.4重量份(其中，车前子壳粉19.4重量份、槐树豆胶10重量份)、L-阿拉伯糖30重量份。
本实施例所述修复糖尿病并发症的组合物制备成食用粉末，具体包括如下步骤：
(a)称取玉米黄质、叶黄素、壳寡糖、透明质酸钠(小分子)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖适量，混合均匀；
(b)混合粉末直接分装成3g/袋；
(c)紫外辐射灭菌即得粉末散剂。
本实施例所述修复糖尿病并发症的食用粉末，用热水冲服，可作为零食或者佐餐食用，可与牛奶同食，可与正餐同食，建议用量为每日3次，每次1袋。
实施例10
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质0.3重量份、叶黄素0.3重量份、壳寡糖10重量份、小分子透明质酸钠(平均分子量为5000道尔顿)10重量份、桑叶提取物10重量份、白芸豆提取物10重量份、膳食纤维20重量份(其中，瓜尔豆胶10重量份、槐树豆胶5重量份，羟丙甲纤维素5重量份)、L-阿拉伯糖39.4重量份。
本实施例所述修复糖尿病并发症的组合物制备成食用糖片，具体步骤包括：
(a)称取玉米黄质、叶黄素、壳寡糖、透明质酸钠(小分子)、桑叶提取物、白芸豆提取物、膳食纤维、L-阿拉伯糖适量，混合均匀；
(b)用5％的75％乙醇制粒，然后在50℃条件下烘干(2h左右)；
(c)过20目筛整粒，压片机压片，3g/片；
(c)紫外辐射灭菌即得糖片。
本实施例所述修复糖尿病并发症的食用糖片，可直接含服、用水吞服或咀嚼后食用，也可作为零食或者佐餐食用，可与牛奶同食，可与正餐同食。建议用量为每日3次，每次1片。
实施例11
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质1重量份、叶黄素二棕榈酸酯1重量份、壳寡糖20重量份、小分子透明质酸钠(平均分子量为1600道尔顿)20重量份、桑叶提取物2重量份、白芸豆提取物15重量份、膳食纤维40重量份(其中，车前子壳粉20重量份、瓜尔豆胶20重量份)、L-阿拉伯糖1重量份。
本实施例所述修复糖尿病并发症的组合物制备成食用粉末，制备方法及食用方法同实施例1。
实施例12
本实施例所述修复糖尿病并发症的组合物，包括：玉米黄质2重量份、叶黄素二棕榈酸酯2重量份、壳寡糖2重量份、小分子透明质酸钠(平均分子量为3000道尔顿)2重量份、桑叶提取物15重量份、白芸豆提取物2重量份、膳食纤维60重量份(其中，车前子壳粉36重量份、瓜尔豆胶24重量份)、L-阿拉伯糖15重量份。
本实施例所述修复糖尿病并发症的组合物制备成食用粉末，制备方法及食用方法同实施例1。
对比例1-9
与实施例1的组合物相比，对比例1中透明质酸钠分子量为500000；对比例2中透明质酸钠分子量为50000；对比例3中透明质酸钠分子量为10000；对比例4中未加入壳寡糖；对比例5中未加入透明质酸钠；对比例6中未加入含氧类胡萝卜素(玉米黄质和叶黄素)；对比例7中未加入白芸豆提取物和桑叶提取物；对比例8中未加入膳食纤维；对比例9中未加入L-阿拉伯糖。
实验例
1、对小鼠血糖、血脂影响的效果实验
实验动物：SPF级雄性昆明小鼠，体重18-22g，室温(20±2)℃，相对湿度45％-55％，光照时间7：00-19：00，自由饮食和饮水。
将70只小鼠随机分为14组：即对照组1(空白对照组)、对照组2(高糖高脂饲料饲养模型组)、实验组1-3(模型给药组)、对比组1-9，其中，
实验组1：取实施例1所述组合物溶于水，制备100mg/mL的浓度，小鼠每日3次灌胃给药，每次0.2mL，连续给药30天；
实验组2：取实施例2所述组合物溶于水，制备100mg/mL的浓度，小鼠每日3次灌胃给药，每次0.2mL，连续给药30天；
实验组3：取实施例3所述组合物溶于水，制备100mg/mL的浓度，小鼠每日3次灌胃给药，每次0.2mL，连续给药30天；
对比组1-9：取对比例1-9所述组合物溶于水，制备100mg/mL的浓度，小鼠每日3次灌胃给药，每次0.2mL，连续给药30天。
对照组1：普通饲料喂养30d，灌胃等量的生理盐水；
对照组2：高糖高脂灭菌全价饲料喂养30d，灌胃等量的生理盐水。
血糖采集和测定：各处理组在连续口服灌胃30d后的第2天，在各组小鼠餐后2h，取小鼠的尾端静脉血检测血糖值；其后，摘眼球采血后脱臼处死，4℃静置1h后3000r/min离心5min，收集血清，-20℃贮藏备用；并在采样后2d内，参照试剂盒说明书指导检测血清中T-CHO、TG、HDL-C、LDL-C等指标进行检测。
统计学方法：试验结果采用X±SD表示，采用Excel进行统计学分析，比较组间差异，P＜0.05为具有极显著差异，有统计学意义。各处理组血糖及血脂检测结果见下表1。
表1各处理组血糖、血脂比较结果
注：*表示与模型组相比有显著性差异。
可见，与正常对照组1相比，高糖高脂饲料饲养的模型组小鼠餐后2h血糖值显著升高，符合糖尿病前期血糖值的范围要求。实验组1-3组小鼠在30天后餐后2h血糖值显著低于模型组。餐后血糖是早期诊断糖尿病的重要指标，代表着葡萄糖负荷后的血糖水平，也对预防糖尿病并发症的发生有着重要作用。可见，本发明所述组合物能显著降低高糖高脂饲料饲养小鼠的餐后血糖，对于早期糖尿病餐后血糖有一定的防治效果。
与正常对照组1相比，高糖高脂饲料饲养得模型组小鼠餐后2h血清T-CHO、TG、LDL-C值升高显著。与模型组相比，实施例处理后，都是使T-CHO、TG和LDL-C值降低，其中，实施例3对与模型组相比，显著降低了T-CHO的浓度；实施例1和2与模型组相比，显著降低了TG的浓度；实施例1与模型组相比，显著降低了LDL-C的浓度。而对HDL-C来说，各组之间都没有显著性差异。这说明本发明所述组合物可以降低高糖高脂饲料饲养小鼠的餐后血清总甘油三酯、总胆固醇和低密脂蛋白的值，而且在某些方面表现的很显著，但不影响高密度脂蛋白的值。
2、对糖尿病足实验模型的研究
实验材料：实验动物为雄性Sprague-Dawley(SD)大鼠70只，清洁级，体质量(180-220g)，饲养环境室温为(23±2)℃，相对湿度为(56±10)％，12小时无光照/12小时人工光照，自由饮食。实验动物随机分为14组，每组5只，即对照组1(糖尿病病足空白对照组)、对照组2、实验组1-3(糖尿病足溃疡模型组)、对比组1-9。
糖尿病模型的制备：对照组1(糖尿病病足空白对照组)、对照组2、实验组1-3(糖尿病足溃疡模型组)高脂饲料喂养8周后，禁食24h，1.5％链脲佐菌素溶解于pH值4.5的柠檬酸-柠檬酸钠缓冲液按35mg/kg的剂量左下腹注射，评价标准：注射24h后血糖大于16.7mml/L，出现多饮多尿，背毛污秽，垫料潮湿，3d后检测血糖仍大于16.7mml/L即判定为糖尿病，随后改为普通饲料喂养。
糖尿病足的制备：1周后，对照组1、2、实验组1-3与采用3％戊巴比妥钠2mL/kg剂量腹腔注射麻醉后，使用SQL-5Q恒温恒压烫伤仪，设置温度90℃，接触时间10s，压力9.8N，选用面积4cm2探头，麻醉后于背部下端皮肤进行烫伤。
评价标准：观察到烫伤处皮肤即刻苍白，肿胀或有水泡出现，24h后取交界区皮肤做病理切片，HE染色观察达到深度Ⅱ烫伤。
各组的治疗方式如下：
对照组1：糖尿病足空白对照，不进行任何处理；
对照组2：糖尿病足溃疡组，采用生理盐水每日换药，阳性组；
实验组1：糖尿病足溃疡组，取实施例1所述组合物溶于水，制备100mg/mL的浓度，大鼠每日3次灌胃给药，每次1.0mL，连续给药30天；
实验组2：糖尿病足溃疡组，取实施例2所述组合物溶于水，制备100mg/mL的浓度，大鼠每日3次灌胃给药，每次1.0mL，连续给药30天；
实验组3：糖尿病足溃疡组，取实施例3所述组合物溶于水，制备100mg/mL的浓度，大鼠每日3次灌胃给药，每次1.0mL，连续给药30天；
对比组1-9：糖尿病足溃疡组，取对比例1-9所述组合物溶于水，制备100mg/mL的浓度，大鼠每日3次灌胃给药，每次1.0mL，连续给药30天。各处理组观察30天后麻醉处死取材。
HE染色：用于肾脏和肝脏的组织形态分析，处死小鼠后，收集新鲜的肾脏和肝脏并在4％多聚甲醛中固定。将石蜡切片以8多聚的厚度切片并用HE溶液染色。拍摄切片图片并使用显微镜进行分析。
免疫组化：在用戊巴比妥钠使大鼠安乐死后收获创面组织。然后将创面组织在4％甲醛缓冲溶液中固定24小时。然后样品在一系列增加的乙醇浓度下进行标准脱水过程24小时。然后，将组织包埋在石蜡中，并使用组织学切片机切片。将组织切片安装在载玻片上，并在加热板上干燥过夜。然后将载玻片在去离子水中洗涤，然后在PBS中洗涤。进行热诱导的抗原修复，将载玻片置于Citrate 6缓冲液(Sigma)中，94℃下20分钟。然后将载玻片在PBS中洗涤并在室温下在0.2％Triton-X-100的PBS溶液中透化10分钟。然后将样品在PBS中的5％山羊血清(微孔)中在室温下封闭1小时。将一抗和二抗在封闭溶液中稀释。将初级抗体CD34+或VEGF中的温育在4℃下孵育过夜，并在二抗(1：200)中在室温下孵育1小时。然后根据制造商的说明在ABC试剂盒(Vectorlabs)和DAB(Vectorlab)溶液中进行样品。
酶联免疫吸附法(ELISA)：根据制造商的说明书，使用市售的ELISA试剂盒(R&DSystems，Minneapolis，MN，USA)测定伤口中炎性细胞因子(包括IL6，CRP和NO-1)的浓度。从标准曲线计算蛋白质浓度，将这些值标准化为由Pierce BCA测定法测定的总蛋白质含量。
蛋白质印迹(Western-Blot)分析：在RIPA缓冲液(Sigma)中裂解伤口组织的总蛋白，包括完整/磷酸酶终止混合物(Millipore)。使用Pierce BCA测定法(Thermo)测量蛋白质浓度。然后通过6％-10％SDS-PAGE分离裂解物(每泳道20裂解)并转移到硝酸纤维素膜上。将转移的膜与封闭溶液[5％牛奶(BD)在TBST中在室温下孵育1小时，然后与第一抗体在4℃下孵育过夜，将膜与HRP-缀合的二抗(Millipore)在室温下孵育1小时。用ECL试剂盒(Millipore)检测免疫反应性，使用Image J(NIH)分析免疫反应性条带的光密度。
RNA分离和real-time PCR：根据制造商的说明书，使用Pure Link RNA Mini Kit(Thermo fisher)从创面组织中分离总RNA。
汞(Hg)冷原子吸收法：汞蒸气对波长253.7nm的紫外光具有强烈的吸收作用，试样经适当处理后，将各种形态的汞转变成汞离子，用氯化亚锡将汞离子还原成元素汞，再用测汞仪进行测定，汞浓度与吸收值成正比。操作方法：准确称取处理好样本置于石英舟中(上盖一小块滤纸)，将石英舟放入管式电炉的石英管里，石英管的一端与氧气瓶连接，另一端与盛有20ml吸收液的吸收管连接。将炉温控制在750℃(吸收管)通氧气(流速L/min)，分段燃烧3min，样品中的汞富集于吸收液中，备作测定。准确吸取一定体积吸收液(燃烧后的)于汞反应瓶中，加入2mL、30％氯化亚锡溶液后立即塞紧瓶塞，开动循环泵，读取最大吸收值。
本实验例中，实验数据符合正态分布的计量资料的采用x研究表示，不符合正态分布的计量资料用中位数表示，利用非参数Mann Whitney U检验两组差异；两组计量资料如服从正态分布且方差齐的用One Way ANOVA单因素方差分析，同组内比较用t-test，组间比较用Student's t检验，方差不齐的校正后再行方差分析；不服从正态分布的采用Nonparametric tests，P<0.05的结果被认为是统计学意义(*P<0.05)。
各处理组快反应蛋白的实验结果中，各处理组炎症因子ELISA的测定结果见附图1，各组血管生成因子的免疫组化结果见附图2，各组炎症相关通路指标WB检结果见附图3。
如图1所示，糖尿病足溃疡大鼠3个实验组(实施例1-3)中炎症因子CRP，IL-6和促炎介质NO的表达比对照组1(空白对照)增加，但与对照组2(阳性组)相比较，实施例1-3治疗显着降低了糖尿病大鼠的炎症因子CRP，IL-6和NO水平。
如图2所示，血管生成在创面愈合中起重要作用，并且与血管生成因子如CD34和VEGF的表达有关。通过免疫化学和RT-PC对CD34，VEGF和E-钙粘蛋白测量创面组织的血管生成和增殖速率。结果显示实验组1-3与对照组1相比较，可增加糖尿病足溃疡大鼠的CD34和VEGF表达。通过RT-PCR测量了VEGF和E-钙粘着蛋白基因的表达。与对照组1相比，对照组2及实验组1-3会降低VEGF的表达量，但与对照比2相比，实验组1-3提高了VEGF的表达量。和与对照组1相比，对照组2及实验组1-3会降低E-钙粘蛋白的表达量，但彼此之间没有显著性差异。
如图3所示，有研究报道显示，糖尿病足溃疡愈合过程中炎症反应较高，也是延迟创面愈合的重要原因。因此，本研究通过对经典炎症相关通路NF和JNK的检测，研究实验组1-3具有能够调节糖尿病足溃疡炎症相关通路的作用。研究结果显示对照组2与对照组1相比NF和JNK信号表达增加，而与对照组2相比，实验组1-3能显著抑制糖尿病足溃疡创面组织中NF和JNK通路的表达，从而降低创面炎症反应强度，促进创面愈合。
因此，本发明所述组合物有促进糖尿病足溃疡愈合的作用，其作用途径包括降低糖尿病足溃疡大鼠炎症因子水平，下调促炎基因NF-炎基和JNK信号通路的表达降低创面炎症反应，增加血管生成因子CD34和VEGF刺激创面血管新生。
3、糖尿病眼病临床实验
选46名糖尿病并伴有眼病的患者，其中男性22、女性24名，分为2组，每组23人：
对照组：每人每次服用安慰剂1片，每日三次；
实验组：每人每次服用实施例2一片，每日三次。
以明视持久度为缓解视力指标，测得的明视持久度增加值越大，表示被测人视力缓解程度越高。
明视持久度的测定方法如下：在检查表上绘制“品”字形立体方块图，方块每边长1cm，局部照明100LX-150LX。测定时，检查表与眼睛的距离应按照受试者视物习惯保持在适当距离不动，规定受试者看到“品”字图像视为明视，倒“品”字时为不明视。测定时间为3min。检查时让受试者手持能断续计时的秒表，检查者发出开始的口令后，受试者立即注视方块中的图案，同时开动手中的秒表计时。在注视过程中看到倒“品”字时立即按下秒表的暂停开关看到又呈“品”字图像时再开动秒表，如此反复进行。测定到规定时间3min结束时受试者听到检查者的口令立即停止秒表，这段时间内秒表走过的读数就是受试者看成“品”字图像的总时间，即明视时间。
明视持久度＝(明视时间/注视总时间)*100％；
以明视持久度为缓解视力指标，明视持久度增加值为实验组内平均值，结果如下表2所示。
表2各处理明视持久度增加值
| 组别 | 服用人数 | 服用周期(天) | 有效率％ | 服用后情况 |
| 对照组 | 23 | 30 | 5％ | 明视持久度增加4％ |
| 实验组 | 23 | 30 | 61％ | 明视持久度增加19％ |
从上表可以看出，本发明所述组合物对糖尿病患者视力的提高有明显的效果。
4、对视力损伤的保护作用
取新西兰家兔，体重2-2.5kg，70只家兔随机分为14组，每组5只，包括正常对照组、模型对照组、实验组1-3(分别为实施例1-3所述组合物)、对比组(分别为对比例1-9所述组合物)：
分别取实施例1-3所述组合物溶于水，分别制备成100mg/mL的药液，实验组1-3中，取新西兰家兔每天灌胃3次，每次5mL，共30天。2个对照组灌等量生理盐水。
分别取对比例1-9所述组合物溶于水，分别制备成100mg/mL的药液，对比组1-9中，取新西兰家兔每天灌胃3次，每次5mL，共30天。
灌胃七天后，将模型对照组和实验组家兔用戊巴比妥钠腹腔注射浅麻醉后，将家兔固定于兔架上，使家兔双眼睁开，将紫外线灯对准家兔双眼，兔角膜距灯管，双眼分别照射30分钟。
泪液中活性和含量的测定：用毛细管分别吸取各只家兔泪液，按照试剂盒说明测定泪液中超氧化物歧化酶(SOD)的活性和丙二醛(MDA)的含量。测试结果见下表3所示。
表3各组对家兔泪液SOD活性及MDA含量影响
可见，各实验组对家兔泪液超氧化物歧化酶(SOD)的活性和丙二醛(MDA)的含量影响的结果下表。结果表明，与正常对照组比较，模型对照组SOD活性明显降低，MDA含量显著升高。MDA是膜脂过氧化最重要的产物之一，它的产生还能加剧膜的损伤因此在衰老生理和抗性生理研究中MDA含量是一个常用指标，可通过MDA了解膜脂过氧化的程度，以间接测定膜系统受损程度以及抗逆性。实验组与模型对照组相比SOD活性均显著提高，MDA含量均显著降低。提示本发明产品可对抗辐射引起的氧化作用。
显然，上述实施例仅仅是为清楚地说明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (10)
1.一种修复糖尿病并发症的组合物，其特征在于，包括0.2-4重量份的含氧类胡萝卜素、2-20重量份的壳寡糖、以及2-20重量份的透明质酸钠。
2.根据权利要求1所述修复糖尿病并发症的组合物，其特征在于，所述含氧类胡萝卜素包括0.1-2重量份的玉米黄质以及0.1-2重量份的叶黄素和/或其酯类。
3.根据权利要求1或2所述修复糖尿病并发症的组合物，其特征在于，所述组合物还包括2-15重量份的桑叶提取物和2-15重量份的白芸豆提取物。
4.根据权利要求1-3任一项所述修复糖尿病并发症的组合物，其特征在于，所述组合物还包括3-60重量份的膳食纤维。
5.根据权利要求1-4任一项所述修复糖尿病并发症的组合物，其特征在于，所述组合物还包括1-50重量份的L-阿拉伯糖。
6.根据权利要求1-5任一项所述修复糖尿病并发症的组合物，其特征在于，所述透明质酸钠的分子量在1200-300000道尔顿之间。
7.由权利要求1-6任一项所述组合物添加可接受的常规辅料、并按照常规工艺制备的修复糖尿病并发症的食品、保健品或药物制剂。
8.根据权利要求7所述的食品、保健品或药物制剂，其特征在于，包括粉剂、颗粒剂、散剂、软糖、果冻、口服液、胶囊、冲剂、片剂或咀嚼片。
9.一种制备权利要求7或8所述食品、保健品或药物制剂的方法，其特征在于，包括取选定量的组合物各组分充分混匀的步骤，以及加入选定辅料混合，并按照常规工艺制成选定剂型的步骤。
10.权利要求1-6任一项所述组合物用于制备修复糖尿病并发症的食品、保健品或药物制剂的用途，其特征在于，所述糖尿病并发症包括降低血糖、降低血脂、糖尿病足、糖尿病眼病。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010923507.XA CN112006282A (zh) | 2020-09-04 | 2020-09-04 | 一种修复糖尿病并发症的组合物及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010923507.XA CN112006282A (zh) | 2020-09-04 | 2020-09-04 | 一种修复糖尿病并发症的组合物及其制备方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112006282A true CN112006282A (zh) | 2020-12-01 |
Family
ID=73515364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010923507.XA Pending CN112006282A (zh) | 2020-09-04 | 2020-09-04 | 一种修复糖尿病并发症的组合物及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112006282A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114098080A (zh) * | 2021-11-18 | 2022-03-01 | 山东沛学生物工程有限公司 | 一种含透明质酸与叶黄素酯的泡腾片及其在酒产品中的应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015127874A1 (zh) * | 2014-02-25 | 2015-09-03 | 湖南希尔天然药业有限公司 | 治疗ii型糖尿病的中药组合物及其制剂和用途 |
| WO2015145389A2 (en) * | 2014-03-28 | 2015-10-01 | Omniactive Health Technologies Limited | Effect of lipophilic nutrients on diabetic eye diseases |
| CN106420454A (zh) * | 2016-09-28 | 2017-02-22 | 北京瑞济善健康科技有限公司 | 用于缓解干眼症和视疲劳的组合物及其制备方法和用途以及走珠施用器 |
| CN106539083A (zh) * | 2016-10-28 | 2017-03-29 | 河南省科高植物天然产物开发工程技术有限公司 | 一种用于预防和治疗糖尿病视网膜病变、缓解视力疲劳的组合物 |
| CN110693028A (zh) * | 2019-10-25 | 2020-01-17 | 陕西中鸿科瑞再生医学研究院有限公司 | 一种降糖减脂组合物 |
| CN110934294A (zh) * | 2019-12-22 | 2020-03-31 | 重庆申高生化制药股份有限公司 | 具有减肥美容功效的组合物及其制备方法 |
-
2020
- 2020-09-04 CN CN202010923507.XA patent/CN112006282A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015127874A1 (zh) * | 2014-02-25 | 2015-09-03 | 湖南希尔天然药业有限公司 | 治疗ii型糖尿病的中药组合物及其制剂和用途 |
| WO2015145389A2 (en) * | 2014-03-28 | 2015-10-01 | Omniactive Health Technologies Limited | Effect of lipophilic nutrients on diabetic eye diseases |
| CN106163536A (zh) * | 2014-03-28 | 2016-11-23 | 奥米尼埃克蒂夫健康科技有限公司 | 亲脂性营养素对糖尿病性眼病的作用 |
| CN106420454A (zh) * | 2016-09-28 | 2017-02-22 | 北京瑞济善健康科技有限公司 | 用于缓解干眼症和视疲劳的组合物及其制备方法和用途以及走珠施用器 |
| CN106539083A (zh) * | 2016-10-28 | 2017-03-29 | 河南省科高植物天然产物开发工程技术有限公司 | 一种用于预防和治疗糖尿病视网膜病变、缓解视力疲劳的组合物 |
| CN110693028A (zh) * | 2019-10-25 | 2020-01-17 | 陕西中鸿科瑞再生医学研究院有限公司 | 一种降糖减脂组合物 |
| CN110934294A (zh) * | 2019-12-22 | 2020-03-31 | 重庆申高生化制药股份有限公司 | 具有减肥美容功效的组合物及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 姚日生主编: "《药用高分子材料》", 30 April 2008, 北京：化学工业出版社 * |
| 无: "中华人民共和国食品安全法", 《HTTP://WWW.GOV.CN/XINWEN/2015-04/25/CONTENT_2852919.HTM》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114098080A (zh) * | 2021-11-18 | 2022-03-01 | 山东沛学生物工程有限公司 | 一种含透明质酸与叶黄素酯的泡腾片及其在酒产品中的应用 |
| CN114098080B (zh) * | 2021-11-18 | 2024-03-29 | 山东沛学生物工程有限公司 | 一种含透明质酸与叶黄素酯的泡腾片及其在酒产品中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108112996A (zh) | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 | |
| US6416795B1 (en) | Herbal extract composition for stress prevention and treatment | |
| WO2008083513A1 (fr) | Extrait de pellicule de soja noir et procédé de préparation et d'utilisation de cet extrait | |
| CN103431390A (zh) | 黑枸杞明目清 | |
| Yampolsky et al. | Apricot (lat. Prunus armeniaca Lin.) | |
| CN112715729A (zh) | 一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 | |
| CN106539083A (zh) | 一种用于预防和治疗糖尿病视网膜病变、缓解视力疲劳的组合物 | |
| CN109400750B (zh) | 一种具有降尿酸作用的药物组合物 | |
| CN103405577A (zh) | 一种增强免疫力、缓解疲劳的药用组合物 | |
| US20070166405A1 (en) | Extracts of houttuynia cordata and rubus coreanus and their composition for preventing and treating allergic diseases | |
| US11191801B2 (en) | Pharmaceutical composition for preventing or treating diabetic complications and angioedema, containing natural mixture extract as active ingredient | |
| CN112006282A (zh) | 一种修复糖尿病并发症的组合物及其制备方法与应用 | |
| KR20080091632A (ko) | 뽕잎, 계피 및 포도씨 추출물을 포함하는 혈당강하용조성물 | |
| CN111165709A (zh) | 一种具有血糖控制功能的固体饮料及其制备方法 | |
| CN114177271A (zh) | 一种调节糖类摄入与控制血糖的组合物及其制备方法 | |
| ES2402643B1 (es) | Combinación de fibra anticolesterolémica | |
| CN105995971A (zh) | 一种促进糖尿病康复的营养流食及其制备方法 | |
| CN109620858A (zh) | 防治糖尿病的药食同源制剂 | |
| KR101835227B1 (ko) | 서목태 추출물을 포함하는 안질환 예방 또는 치료용 조성물 | |
| TW202034790A (zh) | 苦瓜肽組合物 | |
| CN104304487A (zh) | 具有降血糖功效的保健牛奶及其制备方法 | |
| CN111437353A (zh) | 一种辅助降血糖的药食同源植物组合物及其应用 | |
| CN108354143A (zh) | 缓解视疲劳的组合物 | |
| JP5019708B2 (ja) | 糖尿病の治療および予防用組成物 | |
| KR101517828B1 (ko) | 홍삼 복합물을 유효성분으로 함유하는 비만 예방, 개선 또는 치료를 위한 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201201 |
|
| RJ01 | Rejection of invention patent application after publication |